Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
CNY 2.31
(2.67%)
CNY 2.31
(2.67%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.76 Billion CNY | -5.42% |
| 2022 | 1.87 Billion CNY | -16.32% |
| 2021 | 2.23 Billion CNY | -6.17% |
| 2020 | 2.38 Billion CNY | -13.19% |
| 2019 | 2.74 Billion CNY | 16.56% |
| 2018 | 2.35 Billion CNY | -16.74% |
| 2017 | 2.82 Billion CNY | 4.51% |
| 2016 | 2.7 Billion CNY | 55.69% |
| 2015 | 1.73 Billion CNY | 26.82% |
| 2014 | 1.37 Billion CNY | 35.57% |
| 2013 | 1.01 Billion CNY | 21.08% |
| 2012 | 834.85 Million CNY | 37.22% |
| 2011 | 608.41 Million CNY | 67.18% |
| 2010 | 363.93 Million CNY | 130.58% |
| 2009 | 157.83 Million CNY | 25.13% |
| 2008 | 126.13 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 232.94 Million CNY | -32.59% |
| 2024 Q1 | 271.32 Million CNY | -19.78% |
| 2024 Q2 | 345.55 Million CNY | 27.36% |
| 2023 Q2 | 503.23 Million CNY | -7.99% |
| 2023 Q1 | 546.92 Million CNY | -1.13% |
| 2023 Q3 | 395.2 Million CNY | -21.47% |
| 2023 Q4 | 338.2 Million CNY | -14.42% |
| 2023 FY | 1.76 Billion CNY | -5.42% |
| 2022 Q3 | 446.83 Million CNY | 0.59% |
| 2022 Q1 | 426.34 Million CNY | -34.81% |
| 2022 FY | 1.87 Billion CNY | -16.32% |
| 2022 Q4 | 553.15 Million CNY | 23.79% |
| 2022 Q2 | 444.2 Million CNY | 4.19% |
| 2021 FY | 2.23 Billion CNY | -6.17% |
| 2021 Q4 | 653.97 Million CNY | -12.68% |
| 2021 Q2 | 448.63 Million CNY | 16.9% |
| 2021 Q3 | 748.89 Million CNY | 66.93% |
| 2021 Q1 | 383.79 Million CNY | -36.14% |
| 2020 FY | 2.38 Billion CNY | -13.19% |
| 2020 Q1 | 441.08 Million CNY | -44.52% |
| 2020 Q2 | 761.17 Million CNY | 72.57% |
| 2020 Q3 | 579.02 Million CNY | -23.93% |
| 2020 Q4 | 600.98 Million CNY | 3.79% |
| 2019 Q3 | 598.4 Million CNY | 0.17% |
| 2019 Q4 | 795.02 Million CNY | 32.86% |
| 2019 Q2 | 597.38 Million CNY | -20.72% |
| 2019 Q1 | 753.52 Million CNY | -6.76% |
| 2019 FY | 2.74 Billion CNY | 16.56% |
| 2018 Q2 | 495.77 Million CNY | 1.22% |
| 2018 Q4 | 808.15 Million CNY | 44.11% |
| 2018 FY | 2.35 Billion CNY | -16.74% |
| 2018 Q1 | 489.77 Million CNY | -12.33% |
| 2018 Q3 | 560.77 Million CNY | 13.11% |
| 2017 Q2 | 820.03 Million CNY | 5.79% |
| 2017 FY | 2.82 Billion CNY | 4.51% |
| 2017 Q3 | 674.04 Million CNY | -17.8% |
| 2017 Q4 | 558.64 Million CNY | -17.12% |
| 2017 Q1 | 775.16 Million CNY | -4.41% |
| 2016 FY | 2.7 Billion CNY | 55.69% |
| 2016 Q3 | 591.71 Million CNY | -25.48% |
| 2016 Q2 | 794.01 Million CNY | 55.95% |
| 2016 Q4 | 810.94 Million CNY | 37.05% |
| 2016 Q1 | 509.15 Million CNY | -0.14% |
| 2015 Q1 | 294 Million CNY | -24.88% |
| 2015 Q4 | 509.88 Million CNY | 13.63% |
| 2015 Q3 | 448.72 Million CNY | -7.54% |
| 2015 Q2 | 485.32 Million CNY | 65.07% |
| 2015 FY | 1.73 Billion CNY | 26.82% |
| 2014 Q2 | 373.44 Million CNY | 11.77% |
| 2014 Q3 | 271.44 Million CNY | -27.31% |
| 2014 Q4 | 391.36 Million CNY | 44.18% |
| 2014 FY | 1.37 Billion CNY | 35.57% |
| 2014 Q1 | 334.11 Million CNY | -10.12% |
| 2013 Q2 | 213.64 Million CNY | 20.66% |
| 2013 Q3 | 248.39 Million CNY | 16.26% |
| 2013 Q4 | 371.73 Million CNY | 49.66% |
| 2013 FY | 1.01 Billion CNY | 21.08% |
| 2013 Q1 | 177.06 Million CNY | -23.33% |
| 2012 Q3 | 209.99 Million CNY | -5.42% |
| 2012 Q2 | 222.01 Million CNY | 29.17% |
| 2012 FY | 834.85 Million CNY | 37.22% |
| 2012 Q1 | 171.88 Million CNY | 14.32% |
| 2012 Q4 | 230.96 Million CNY | 9.98% |
| 2011 Q1 | 138.35 Million CNY | -3.82% |
| 2011 Q2 | 172.69 Million CNY | 24.82% |
| 2011 Q4 | 150.34 Million CNY | 2.26% |
| 2011 Q3 | 147.02 Million CNY | -14.86% |
| 2011 FY | 608.41 Million CNY | 67.18% |
| 2010 FY | 363.93 Million CNY | 130.58% |
| 2010 Q4 | 143.84 Million CNY | 50.52% |
| 2010 Q3 | 95.56 Million CNY | 0.0% |
| 2009 FY | 157.83 Million CNY | 25.13% |
| 2008 FY | 126.13 Million CNY | 0.0% |